KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $99 | $32 | $56 | $31 |
| Short-Term Investments | $89 | $179 | $93 | $135 |
| Receivables | $15 | $11 | $19 | $17 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $39 | $4 | $4 | $11 |
| Total Curr. Assets | $242 | $226 | $172 | $194 |
| Property Plant & Equip (Net) | $2 | $9 | $11 | $10 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $7 | $1 | $0 | $0 |
| Total NC Assets | $9 | $10 | $11 | $10 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $251 | $235 | $183 | $204 |
| Liabilities | – | – | – | – |
| Payables | $5 | $9 | $5 | $4 |
| Short-Term Debt | $2 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $11 | $0 | $0 | $0 |
| Other Curr. Liab. | $27 | $12 | $9 | $7 |
| Total Curr. Liab. | $45 | $23 | $15 | $12 |
| LT Debt | $4 | $6 | $7 | $7 |
| Deferred Rev, NC | $106 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $110 | $6 | $7 | $7 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $6 | $7 | $8 | $8 |
| Total Liabilities | $155 | $29 | $22 | $19 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$653 | -$470 | -$343 | -$250 |
| AOCI | -$5 | -$3 | -$3 | -$4 |
| Other Equity | $754 | $680 | $507 | $439 |
| Total Equity | $95 | $207 | $161 | $185 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $251 | $235 | $183 | $204 |
| Net Debt | -$92 | -$24 | -$48 | -$23 |